
South San Francisco, California, United States
Firefly specializes in Degrader Antibody Conjugates (DACs) which combine the unique strengths of ADCs with selective protein degraders, developing a novel platform to treat cancer.
- Revenue
- $7.4M
- Customers
- -
- Year founded
- 2022
- Funding
- -
- Team size
- 28
- Growth
- -

